Lipocine

Health biotech compliance drug development life sciences pharma

Lipocine is a specialty pharmaceutical company developing pharmaceutical products using its oral drug delivery technology in the areas of men's and women's health. The Company offers a portfolio of proprietary product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is LPCN 1021, an oral testosterone replacement therapy.

Market capitalization(2018-04-20)

$33.1 M

Type

Public

Salt Lake City, US

Founded

1997

Size (employees)

14 (est)

Website

lipocine.com

Lipocine was founded in 1997 and is headquartered in Salt Lake City, US

Report incorrect company information

Key People/Management at Lipocine

Mahesh Patel

Chairman, President and Chief Executive Officer

Morgan Brown

Executive Vice President and Chief Financial Officer

Greg Bass

Executive Vice President and Chief Commercial Officer

Jyrki Mattila

Executive Vice President and Chief Business Officer

Anthony DelConte

Chief Medical Director

Report incorrect company information

Lipocine Office Locations

Lipocine has offices in Lawrence and Salt Lake City

Salt Lake City, US (HQ)

202 675 Arapeen Dr

Lawrence, US

3150 Brunswick Pike, Suite 130

Show all (2)

Report incorrect company information

Lipocine Financials and Metrics

Lipocine Financials

Summary

USD
Net income (FY, 2017)	(21 m)
EBIT (FY, 2017)	(21.2 m)
Market capitalization (20-Apr-2018)	33.1 m
Cash (31-Dec-2017)	3.2 m

Lipocine's current market capitalization is $33.1 m.

Income Statement

Annual

USD	Y, 2013	FY, 2016	FY, 2017
General and administrative expense		10.4 m	10.2 m
R&D expense		8.1 m	11 m
Operating expense total		18.5 m	21.2 m
EBIT	(10.7 m)	(19.2 m)	(21.2 m)

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q3, 2017
General and administrative expense	1.2 m	1.9 m	1 m	871.8 k	1.1 m	1.1 m	1.7 m	4.4 m	3.2 m	1.4 m	1.8 m	2 m
R&D expense	1.6 m	3.4 m	6 m	3.2 m	1.9 m	3.2 m	4.7 m	2.7 m	2.6 m	1.5 m	3.1 m	4.1 m
Operating expense total	2.8 m	5.3 m	7 m	4.1 m	3 m	4.3 m	6.4 m	7.1 m	5.8 m	3.3 m	4.9 m	6.1 m	4.8 m
EBIT	(3.5 m)	(5.3 m)	(7 m)	(4.1 m)	(3 m)	(4.3 m)	(6.4 m)	(7.1 m)	(5.8 m)	(3.3 m)	(4.9 m)	(6.1 m)	(4.8 m)

show all

Balance Sheet

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Cash	45.3 m	27.7 m	20 m	5.6 m	3.2 m
Accounts Receivable
Inventories
Current Assets	46 m	27.9 m	44.9 m	27.2 m	25.2 m

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q3, 2017
Cash	36.8 m	41.8 m	34.2 m	31.7 m	24.8 m	38.3 m	23.9 m	14.1 m	12.4 m	4.7 m	6.9 m	16.6 m	9.3 m
Current Assets	37.1 m	42 m	35.4 m	32 m	25 m	44.1 m	42.3 m	38.6 m	33.2 m	29.4 m	27.1 m	27.9 m	26.1 m
Total Assets	37.2 m	42.1 m	35.5 m	32 m	25.1 m	53.8 m	48.4 m	38.8 m	33.3 m	29.6 m	27.2 m	28 m	26.3 m
Accounts Payable	1.5 m	773 k	641.8 k	399.1 k	379.5 k	398.8 k	456.8 k	1.1 m	989 k	865 k	853.5 k	1.1 m	803.8 k

show all

Cash Flow

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Net Income	(10.6 m)	(20.4 m)	(18.2 m)	(19 m)	(21 m)
Depreciation and Amortization	21.8 k	14.6 k	26.7 k	32 k	28.4 k
Inventories
Accounts Payable	668.8 k	(449.6 k)	200.8 k	(261.2 k)	352.2 k

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q3, 2017
Net Income	(3.5 m)	(5.3 m)	(7 m)	(4.1 m)	(3 m)	(4.2 m)	(6.4 m)	(7 m)	(5.8 m)	(3.2 m)	(4.9 m)	(4.7 m)
Accounts Payable			641.8 k	399.1 k	379.5 k	398.8 k	456.8 k	1.1 m	989 k	865 k	853.5 k	803.8 k